1. The sympathomimetic agonist mirabegron did not lower JAK2-V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: results of phase II study SAKK 33/14
- Author
-
Drexler, Beatrice, Passweg, Jakob R, Tzankov, Alexandar, Bigler, Martin, Theocharides, Alexandre Pa, Cantoni, Nathan, Keller, Peter, Stussi, Georg, Ruefer, Axel, Benz, Rudolf, Favre, Geneviève, Lundberg, Pontus, Nienhold, Ronny, Fuhrer, Andrea, Biaggi, Christine, Manz, Markus G, Bargetzi, Mario, Mendez-Ferrer, Simon, Skoda, Radek C, Swiss Group For Clinical Cancer Research (SAKK), Mendez-Ferrer, Simon [0000-0002-9805-9988], and Apollo - University of Cambridge Repository
- Subjects
Adult ,Male ,Myeloproliferative Disorders ,Mutation, Missense ,Janus Kinase 2 ,Middle Aged ,Fibrosis ,Nestin ,Mice ,Reticulin ,Thiazoles ,Amino Acid Substitution ,hemic and lymphatic diseases ,Hematologic Neoplasms ,Animals ,Humans ,Acetanilides ,Female ,Sympathomimetics - Abstract
The β-3 sympathomimetic agonist BRL37344 restored nestin-positive cells within the stem cell niche, and thereby normalized blood counts and improved myelofibrosis in a mouse model of JAK2-V617F-positive myeloproliferative neoplasms. We therefore tested the effectiveness of mirabegron, a β-3 sympathomimetic agonist, in a phase II trial including 39 JAK2-V617F-positive patients with myeloproliferative neoplasms and a mutant allele burden more than 20%. Treatment consisted of mirabegron 50 mg daily for 24 weeks. The primary end point was reduction of JAK2-V617F allele burden of 50% or over, but this was not reached in any of the patients. One patient achieved a 25% reduction in JAK2-V617F allele burden by 24 weeks. A small subgroup of patients showed hematologic improvement. As a side study, bone marrow biopsies were evaluated in 20 patients. We found an increase in the nestin+ cells from a median of 1.09 (interquartile range 0.38-3.27)/mm2 to 3.95 (interquartile range 1.98-8.79)/mm2 (P
- Published
- 2019